These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32709718)

  • 41. Enhanced Antibacterial Activity of Acinetobacter baumannii Bacteriophage ØABP-01 Endolysin (LysABP-01) in Combination with Colistin.
    Thummeepak R; Kitti T; Kunthalert D; Sitthisak S
    Front Microbiol; 2016; 7():1402. PubMed ID: 27656173
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lytic transglycosylase contributes to the survival of lipooligosaccharide-deficient, colistin-dependent Acinetobacter baumannii.
    Lee JY; Lee H; Park M; Cha CJ; Shin D; Ko KS
    Clin Microbiol Infect; 2019 Sep; 25(9):1156.e1-1156.e7. PubMed ID: 30790686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
    Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
    Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.
    Cai Y; Chai D; Wang R; Liang B; Bai N
    J Antimicrob Chemother; 2012 Jul; 67(7):1607-15. PubMed ID: 22441575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impaired growth under iron-limiting conditions associated with the acquisition of colistin resistance in Acinetobacter baumannii.
    López-Rojas R; García-Quintanilla M; Labrador-Herrera G; Pachón J; McConnell MJ
    Int J Antimicrob Agents; 2016 Jun; 47(6):473-7. PubMed ID: 27179817
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular Mechanisms of Colistin Resistance Among Pandrug-Resistant Isolates of Acinetobacter baumannii with High Case-Fatality Rate in Intensive Care Unit Patients.
    Haeili M; Kafshdouz M; Feizabadi MM
    Microb Drug Resist; 2018 Nov; 24(9):1271-1276. PubMed ID: 29590004
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Prospective Study of
    Leung LM; McElheny CL; Gardner FM; Chandler CE; Bowler SL; Mettus RT; Spychala CN; Fowler EL; Opene BNA; Myers RA; Goodlett DR; Doi Y; Ernst RK
    J Clin Microbiol; 2019 Mar; 57(3):. PubMed ID: 30567747
    [No Abstract]   [Full Text] [Related]  

  • 48. Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains.
    Lo-Ten-Foe JR; de Smet AM; Diederen BM; Kluytmans JA; van Keulen PH
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3726-30. PubMed ID: 17646414
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New Class of Adjuvants Enables Lower Dosing of Colistin Against Acinetobacter baumannii.
    Minrovic BM; Jung D; Melander RJ; Melander C
    ACS Infect Dis; 2018 Sep; 4(9):1368-1376. PubMed ID: 29890069
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antimicrobial activity of photodynamic therapy in combination with colistin against a pan-drug resistant Acinetobacter baumannii isolated from burn patient.
    Boluki E; Kazemian H; Peeridogaheh H; Alikhani MY; Shahabi S; Beytollahi L; Ghorbanzadeh R
    Photodiagnosis Photodyn Ther; 2017 Jun; 18():1-5. PubMed ID: 28088439
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials.
    Gordillo Altamirano F; Forsyth JH; Patwa R; Kostoulias X; Trim M; Subedi D; Archer SK; Morris FC; Oliveira C; Kielty L; Korneev D; O'Bryan MK; Lithgow TJ; Peleg AY; Barr JJ
    Nat Microbiol; 2021 Feb; 6(2):157-161. PubMed ID: 33432151
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Novel
    Khan FM; Gondil VS; Li C; Jiang M; Li J; Yu J; Wei H; Yang H
    Front Cell Infect Microbiol; 2021; 11():637313. PubMed ID: 33738267
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance.
    Wand ME; Bock LJ; Bonney LC; Sutton JM
    J Antimicrob Chemother; 2015 Aug; 70(8):2209-16. PubMed ID: 25904728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii.
    Rodríguez-Hernández MJ; Saugar J; Docobo-Pérez F; de la Torre BG; Pachón-Ibáñez ME; García-Curiel A; Fernández-Cuenca F; Andreu D; Rivas L; Pachón J
    J Antimicrob Chemother; 2006 Jul; 58(1):95-100. PubMed ID: 16636085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resistance to bacteriophage incurs a cost to virulence in drug-resistant
    Manley R; Fitch C; Francis V; Temperton I; Turner D; Fletcher J; Phil M; Michell S; Temperton B
    J Med Microbiol; 2024 May; 73(5):. PubMed ID: 38743467
    [No Abstract]   [Full Text] [Related]  

  • 56. Colistin/daptomycin: an unconventional antimicrobial combination synergistic in vitro against multidrug-resistant Acinetobacter baumannii.
    Galani I; Orlandou K; Moraitou H; Petrikkos G; Souli M
    Int J Antimicrob Agents; 2014 Apr; 43(4):370-4. PubMed ID: 24560919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
    Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
    J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Gazel D; Tatman Otkun M; Akçalı A
    J Med Microbiol; 2019 Nov; 68(11):1607-1613. PubMed ID: 31535963
    [No Abstract]   [Full Text] [Related]  

  • 59. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains.
    Li J; Nation RL; Owen RJ; Wong S; Spelman D; Franklin C
    Clin Infect Dis; 2007 Sep; 45(5):594-8. PubMed ID: 17682994
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
    Thomas VM; Brown RM; Ashcraft DS; Pankey GA
    Int J Antimicrob Agents; 2019 May; 53(5):663-668. PubMed ID: 30880230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.